FUNDING CANCER - Assay Development & Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (R01 Clinical Trial Not Allowed)
Sponsor: National Institutes of Health
Description: Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.
- Next Application Deadline: October 5, 2024
-
Future Deadlines:
-
February 5, 2025
- June 5, 2025
- October 5, 2025
- February 5, 2026
- June 5, 2026
To view all current UVACCC funding opportunities, please click here.
For all open cancer-related funding opportunities, please click here.